Arbutus Biopharma (ABUS) Operating Leases (2019 - 2025)

Arbutus Biopharma has disclosed Operating Leases across 7 years of filings, most recently posting $199000.0 for Q4 2025.

• Operating Leases for Q4 2025 came in at $199000.0, down 75.31% year-over-year; the trailing twelve-month figure through Dec 2025 was $199000.0 (down 75.31% YoY), and the FY2025 annual result was $199000.0, down 75.31% from the prior year.
• Operating Leases came in at $199000.0 for Q4 2025 at Arbutus Biopharma, down from $391000.0 in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $2.5 million in Q1 2021 to a low of $199000.0 in Q4 2025.
• The 5-year median for Operating Leases is $1.6 million (2023), against an average of $1.5 million.
• Across the five-year window, Operating Leases declined 13.67% in 2021 and plunged 75.31% in 2025, its largest moves.
• Arbutus Biopharma's Operating Leases stood at $2.2 million in 2021, then slipped by 18.65% to $1.8 million in 2022, then fell by 26.01% to $1.3 million in 2023, then slumped by 39.99% to $806000.0 in 2024, then slumped by 75.31% to $199000.0 in 2025.
• The last three Operating Leases figures came in at $199000.0 (Q4 2025), $391000.0 (Q3 2025), and $575000.0 (Q2 2025), per Business Quant data.